A new manufacturing process developed by researchers at the Center for High-rate Nanomanufacturing (CHN) at Northeastern University produces nanoparticle structures with a unique ability to pass through normal tissue boundaries. Dr. Ahmed Busnaina, the Director of the CHN, has found that nano-sized particles can be fabricated into distinct shapes, such as nanopillars. With their controlled size and shape, these nanopillars could potentially have high tissue permeability. This process could have far-reaching impacts, including important applications within the pharmaceutical industry where some drugs must be administered by IV or injection, but would now be able to be delivered orally.
The Technology Evaluation ConsortiumTM (TEC), managed by One Million Solutions in HealthTM, is managing an evaluation of the CHN’s patented process within the pharmaceutical industry. In particular, the consortium is examining how the process can incorporate compounds, such as poorly water-soluble drugs, into an assembly of fully functional nanoparticle structures.
This would create drug-loaded nanostructures with high tissue permeability, which could allow effective transport through the stomach. The nanostructures would then pass directly into the bloodstream. This would allow for oral delivery of poorly soluble drugs that are either currently undeliverable or are delivered through challenging ways.
A successful project between One Million Solution in Health’s TEC and the CHN will lead to a significant advancement in one segment of the pharmaceutical industry. However, a breakthrough like this should not be surprising for either party. The Technology Evaluation Consortium has completed many successful projects since its founding, and Northeastern’s faculty constantly pursue a high level of use-inspired, interdisciplinary research with a focus on discovering solutions to global challenges in health, security and sustainability.
The consortium is bringing together a number of industry leaders from pharmaceutical companies to evaluate, validate and further qualify the CHN’s patented process. Consortium members and pharma experts affiliated with the university will share ideas and solutions with the hopes of creating a likely path of adoption for Northeastern University’s nanoparticle technology. Interest among pharmaceutical companies has been high for this exciting project that could greatly change pharmaceutical research and development.
ABOUT NORTHEASTERN UNIVERSITY AND THE CENTER FOR HIGH-RATE NANOMANUFACTURING
The Center for High-rate Nanomanufacturing (CHN) at Northeastern University in Boston is focused on developing tools and processes that will make it possible for businesses to quickly and efficiently manufacture products that have unique characteristics due to their size and shape. The CHN’s work on advancing our capacity to make high-rate, value-added products using nanoparticles and specialized processes is one of many initiatives that are making the university a leader in nanotechnology
Northeastern’s advances in affective science, drug discovery and delivery, personal health informatics, and sensors are characterized by global collaborations with industry, government, and other academic institutions. Its leadership in nanotechnology and data science provides a growing technological foundation for new discoveries in these and other areas of interdisciplinary research. www.nanomanufacturing.us
ABOUT ONE MILLION SOLUTIONS IN HEALTH
The goal of One Million Solutions in Health™ is to shape health care by sharing solutions and, importantly, to accelerate the discovery, development and delivery … of innovative cures, treatments and preventative measures for patients around the world.
In this next year, we will be reviewing 1000′s of new solutions and new scientific discoveries. By engaging scientists, entrepreneurs, investors, innovators, industry experts, health care professionals, and patients across various disciplines, and from around the world, we can utilize the power of the internet to disrupt things in a positive and transformative way to accelerate the movement of new solutions and scientific discoveries from the scientist to the patient.
We are on our way towards accelerating high-potential innovations, catalyzing investment and increasing awareness of, and support for, transformative ideas to improve health and save lives. By facilitating efforts to ensure organizations can Connect, Learn + Share, Innovate and Collaborate, our vision is to improve health care delivery, accelerate life sciences research and share patient and consumer-focused ideas and solutions.
As a not-for-profit, we welcome your participation and are thrilled to have you be a part of this transformative journey!
ABOUT THE TECHNOLOGY EVALUATION CONSORTIUM
The Technology Evaluation Consortium™ from One Million Solutions in Health™ is dedicated to improving and accelerating life sciences R&D and health care outcomes. The Technology Evaluation Consortium brings together life sciences and/or health care companies and industry vendors or scientists, and other relevant partners (e.g., government and Universities), to evaluate and validate technologies or services in a collaborative environment.
The model empowers technology providers/scientists and industry end-users to collectively assess a number of solutions in a cost-effective manner, producing a depth and breadth of results that no company can achieve alone. Our mission is to triage and streamline new technology consideration for the industry and to be the place for the industry to conduct their evaluations and validations.
Dawn Van Dam
President and CEO